Randomized double-blind study of prophylactic treatment with an antihistamine for seasonal allergic rhinitis

International Archives of Allergy and Immunology

Volumn 162, Issue 1, 2013, Pages 71-78

  Yonekura, Syuji ^a   Okamoto, Yoshitaka ^a   Yamamoto, Heizaburo ^a   Sakurai, Toshioki ^a   Iinuma, Tomohisa ^a   Sakurai, Daiju ^a   Hanazawa, Toyoyuki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Antihistamine; Early intervention; Environmental challenge chamber; Prophylactic treatment; Seasonal allergic rhinitis

Indexed keywords

LEVOCETIRIZINE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; JAPANESE CEDAR; MALE; POLLEN ALLERGY; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SOMNOLENCE; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION;

EID: 84879480395     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000350926     Document Type: Article

References (29)

1. Bousquet J, Khaltaev N, Cruz AA, et al; World Health Organization; GA(2)LEN; AllerGen: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63(suppl 86):8-160.
2. Practical Guideline for the Management of Allergic Rhinitis in Japan: Perennial Rhinitis and Pollinosis, ed 6. Tokyo, Life Science, 2008.
3. Kaneko Y, Motohashi Y, Nakamura H, Endo T, Eboshida A. Increasing prevalence of Japanese cedar pollinosis: a meta-regression analysis. Int Arch Allergy Immunol 2005; 136: 365-371.
4. Okuda M. Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003; 91: 288-296.
5. Dolovich J, Moote DW, Mazza JA, Clermont A, PetitClerc C, Danzig M. Efficacy of loratadine versus placebo in the prophylactic treatment of seasonal allergic rhinitis. Ann Allergy 1994; 73: 235-239.
6. Kurowski M, Kuna P, Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004; 59: 280-288.
7. Sasaki K, Okamoto Y, Yonekura S, Okawa T, Horiguchi S, Chazono H, Hisamitsu M, Sakurai D, Hanazawa T, Okubo K. Cedar and cypress pollinosis and allergic rhinitis: quality of life effects of early intervention with leukotriene receptor antagonists. Int Arch Allergy Immunol 2009; 149: 350-358.
8. Pitsios C, Papadopoulos D, Kompoti E, Manoussakis E, Garris V, Petalas K, Tassios I, Baibas N, Kontou-Fili K, Saxoni-Papageorgiou P, Papadopoulos NG. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/ severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96: 673-678.
9. Graft D, Aaronson D, Chervinsky P, Kaiser H, Melamed J, Pedinoff A, Rosen JP, Schenkel EJ, Vandewalker ML, Keim A, Jensen PK, Nolop K, Mesarina-Wicki B. A placebo-And activecontrolled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996; 98: 724-731.
10. Roquat A, Ihre E, Van Hage-Hamsten M, Hallden G, Zetterström O. Allergen-induced inflammation in the nose: a comparison of acute and repeated low-dose allergen exposure. Allergy 1996; 51: 42-48.
11. Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R. Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma-And G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001; 60: 1133-1142.
12. Bakker RA, Wieland K, Timmerman H, Leurs R. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur J Pharmacol 2000; 387:R5-R7.
13. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry. Allergic Rhinitis: Clinical Development Programs for Drug Products. Draft Guidance. 2000. http://www.fda.gov/downloads/Drugs/Guidan ceComplianceRegulatoryInformation/Guid ances/ucm071293.pdf.
14. Yamamoto H, Yonekura S, Sakurai D, Katada K, Inamine A, Hanazawa T, Horiguchi S, Okamoto Y. Comparison of nasal steroid with anti-histamine in prophylactic treatment against pollinosis using an environmental challenge chamber. Allergy Asthma Proc 2012; 33: 397-403.
15. Muradil M, Okamoto Y, Yonekura S, Chazono H, Hisamitsu M, Horiguchi S, Hanazawa T, Takahashi Y, Yokota K, Okumura S. Reevaluation of pollen quantitation by an automatic pollen counter. Allergy Asthma Proc 2010; 31: 422-427.
16. Gerth Van Wijk RG, de Graaf-in 't Veld C, Garrelds IM. Nasal hyperreactivity. Rhinology 1999; 37: 50-55.
17. Naclerio RM, Proud D, Togias AG, Adkinson NF Jr, Meyers DA, Kagey-Sobotka A, Plaut M, Norman PS, Lichtenstein LM. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313: 65-70.
18. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001; 107: 469-476.
19. Semik-Orzech A, Barczyk A, Wiaderkiewicz R, Pierzchala W. Eotaxin, but not IL-8, is increased in upper and lower airways of allergic rhinitis subjects after nasal allergen challenge. Allergy Asthma Proc 2011; 32: 230-238.
20. Sergejeva S, Malmhäll C, Lötvall J, Pullerits T. Increased number of CD34+ cells in nasal mucosa of allergic rhinitis patients: inhibition by a local corticosteroid. Clin Exp Allergy 2005; 35: 34-38.
21. KleinJan A, McEuen AR, Dijkstra MD, Buckley MG, Walls AF, Fokkens WJ. Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. J Allergy Clin Immunol 2000; 106: 677-686.
22. Dinh QT, Cryer A, Trevisani M, Dinh S, Wu S, Cifuentes LB, Feleszko WK, Williams A, Geppetti P, Fan Chung K, Heppt W, Klapp BF, Fischer A. Gene and protein expression of protease-Activated receptor 2 in structural and inflammatory cells in the nasal mucosa in seasonal allergic rhinitis. Clin Exp Allergy 2006; 36: 1039-1048.
23. Reed CE, Kita H. The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol 2004; 114: 997-1008.
24. Raap U, Fokkens W, Bruder M, Hoogsteden H, Kapp A, Braunstahl GJ. Modulation of neurotrophin and neurotrophin receptor expression in nasal mucosa after nasal allergen provocation in allergic rhinitis. Allergy 2008; 63: 468-475.
25. Sheahan P, Walsh RM, Walsh MA, Costello RW. Induction of nasal hyper-responsiveness by allergen challenge in allergic rhinitis: the role of afferent and efferent nerves. Clin Exp Allergy 2005; 35: 45-51.
26. Thomson L, Blaylock MG, Sexton DW, Campbell A, Walsh GM. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 2002; 32: 1187-1192.
27. Giustizieri ML, Albanesi C, Fluhr J, Gisondi P, Norgauer J, Girolomoni G. H1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004; 114: 1176-1182.
28. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J, Van Cauwenberge PB, Van Hammee G; XPERT Study Group: Levocetirizine improves quality of life and reduces costs in long-Term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004; 114: 838-844.
29. Potter PC; Study Group: Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy 2003; 58: 893-899.